REVIVA PHARMA HLDGS INC
RVPH
RVPH was delisted on the 13th of May, 2026.
16 hedge funds and large institutions have $33.5M invested in REVIVA PHARMA HLDGS INC in 2020 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 10 closing their positions.
1.52% less ownership
Funds ownership: 3.56% → 2.04% (-1.5%)
33% less funds holding
Funds holding: 24 → 16 (-8)
42% less capital invested
Capital invested by funds: $57.4M → $33.5M (-$23.9M)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
80% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$1.05M |
| 2 |
AGM
Alpine Global Management
New York
|
+$684K |
| 3 |
FTCM
First Trust Capital Management
Chicago,
Illinois
|
+$1.92K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$426 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$7.29M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$3.48M |
| 3 |
MSU
Mizuho Securities USA
New York
|
-$3.37M |
| 4 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$2.54M |
| 5 |
WRBC
W.R. Berkley Corp
Greenwich,
Connecticut
|
-$2.26M |
RVPH Hedge Fund Activity: Q2 2020 in Review
16 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in REVIVA PHARMA HLDGS INC (RVPH) for Q2 2020, worth a combined $33.5M — down 42% from $57.4M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of RVPH and 2 opened new positions — a net loss of 8 holders — while 4 trimmed existing stakes and 2 added.
The largest buyer was Polar Asset Management Partners, adding an estimated $1.05M. The largest seller was Bank of Montreal, exiting entirely with an estimated $7.29M sold.
- 16 institutional investors held REVIVA PHARMA HLDGS INC (RVPH) as of Q2 2020, down from 24 in Q1 2020.
- Funds reported $33.5M of REVIVA PHARMA HLDGS INC stock for Q2 2020, down 42% quarter-over-quarter.
- 2 funds opened new REVIVA PHARMA HLDGS INC positions in Q2 2020 and 10 closed out, a net change of -8 holders.
- The largest REVIVA PHARMA HLDGS INC buyer in Q2 2020 was Polar Asset Management Partners, an estimated $1.05M added.
- The largest REVIVA PHARMA HLDGS INC seller in Q2 2020 was Bank of Montreal, an estimated $7.29M sold.
Based on aggregated 13F filings for Q2 2020.